CATT: Comparison of Age-Related Macular Degeneration Treatments Trials

Overview CATT Study

Gegenwart, DBSV-Mitgliedermagazin, Ausgabe Juli/August 2011

Das eine Medikament teuer und zugelassen, das andere sehr viel preiswerter, aber nicht zugelassen: Seit Jahren schwelt ein heftiger Konflikt um die Therapie bei feuchter AMD (Altersabhängige Makula-Degeneration). Entsprechend groß ist das Interesse an einer US-amerikanischen Vergleichsstudie. Das erste Ergebnis: Lucentis und Avastin wirken annähernd gleich gut.

Weiterlesen: Avastin und Lucentis Kopf an Kopf

04. Mai.2011: Gemeinsame Pressemitteilung von DOG, RG und BVA zur CATT-Studie

Amerikanische Studie zeigt gleich gute Ergebnisse für Ranibizumab (Lucentis®) und Bevacizumab (Avastin®) in der Behandlung der feuchten Makuladegeneration

Weiterlesen: Pressemitteilung von DOG, RG und BVA zur CATT-Studie

May 02, 2011, ARVO: Two-Year Safety Equal in AMD Drug Trial

Preliminary two-year safety data from the landmark CATT trial of biologic drugs for macular degeneration partially reversed conclusions from the one-year results reported last week, study leaders said in an oral presentation Sunday.

02.05.2011, Deutsche Apotheker Zeitung: Avastin und Lucentis sind gleichwertig

Eine großangelegte randomisierte Studie konnte erstmalig belegen, dass eine Behandlung der altersbedingten Makuladegeneration (AMD) mit Ranibizumab (Lucentis) oder Bevacizumab (Avastin) zu vergleichbaren Ergebnissen führt.

Weiterlesen: Avastin und Lucentis sind gleichwertig

April 28, 2011, ARVO: Age-Related Macular Degeneration Drugs Equal

After one year, bevacizumab appears to be as effective as ranibizumab in improving visual acuity associated with age-related macular degeneration when administered on the same schedule, according to a study published online April 28 in the New England Journal of Medicine in advance of a presentation at the annual meeting of the Association for Research in Vision and Ophthalmology, to be held from May 1 to 5 in Fort Lauderdale, Fla.

28. April 2011: Roche will Lucentis weiter für altersbedingte Makuladegeneration entwickeln

Der Pharmakonzern Roche will das Medikament Lucentis weiterhin für "nasse" altersbedingte Makuladegeneration (AMD) entwickeln. Die Publikation von Daten der CATT-Studie im "New England Journal of Medicine" liefere wichtige Informationen über zwei Behandlungsformen für AMD.

Weiterlesen: Roche will Lucentis weiter für altersbedingte Makuladegeneration entwickeln

April 28, 2011, AMDAI Responds to CATT Trials Research

"As an organization representing more than 30 million people around the world living with age-related macular degeneration, we have been anxiously awaiting the results of the CATT study," said AMD Alliance International CEO, Narinder Sharma.

28. April 2011, aerzteblatt.de - US-Studie: Avastin und Lucentis offenbar gleichwertig

Eine Vergleichsstudie des US-National Eye Institute ist offenbar zu dem Ergebnis gekommen, dass die beiden Wirkstoffe Bevacizumab (Avastin) und Ranibizumab (Lucentis) in der Behandlung der feuchten AMD gleichwertig sind.

Weiterlesen: US-Studie: Avastin und Lucentis offenbar gleichwertig

April 28, 2011, wkyc.com: Cheaper drug found to treat macular degeneration equally

A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD).

April 28, 2011, nih.gov: NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration

April 27, 2011, invivoblog.blogspot.com: Preparing for the CATT Study: Will Makena Controversy Have an Impact?

The first public presentation of data from the National Eye Institute's head-to-head study of Lucentis vs. Avastin in macular degeneration will take place this weekend. The Comparison of Age-Related Macular Degeneration Treatments Trial (CATT) is sure to go down as an early landmark in the era of comparative effectiveness research - though exactly how it will be remembered is less clear.

April 20, 2011, reuters.com: Head-to-head eye drug results confirmed for May 1

Results of a key study comparing Roche and Novartis's eye treatment Lucentis with low doses of cancer drug Avastin will, as predicted, be presented at the ARVO medical meeting on May 1.

Mar 30, 2011, reuters.com: Lucentis vs Avastin study may feature at May 1-5 congress

Results of the so-called CATT study comparing Roche (ROG.VX) and Novartis's (NOVN.VX) eye drug Lucentis with low doses of cancer treatment Avastin may be presented at a medical meeting in early May.

Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

The Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) is a multi-centered randomized clinical trial to assess the relative safety and efficacy of two treatments for subfoveal neovascular Age-Related Macular Degeneration (AMD), a disease that usually causes severe irreversible vision loss. CATT will be conducted in 44 clinical centers and is funded by the National Eye Institute.